Phase III X-TOLE2 data support azetukalner filing in focal onset seizures
Xenon Pharmaceuticals reported positive Phase III X-TOLE2 results for azetukalner in focal onset seizures. The company plans an FDA new drug application in Q3 2026.
Benzodiazepines
DrugRelated News
Overdose Deaths Decline as Drug Market Evolves with Dangerous Polydrug Cocktails
U.S. overdose deaths declined 19% year-over-year to 72,108 for the 12 months ending September 2025, but the drug market is evolving with dangerous polydrug cocktails like "pink cocaine" and "rhino tranq" that are harder to detect and reverse. These synthetic blends combine fentanyl with stimulants, sedatives, and veterinary tranquilizers, creating new public health challenges as naloxone becomes less effective against complex overdoses.
B.C. toxic drug deaths decline 21% in 2025 as fentanyl concentrations drop
British Columbia recorded 1,826 unregulated drug toxicity deaths in 2025, a 21% decrease from 2024. New research links the decline to decreasing fentanyl concentrations in the illicit drug supply, though nearly five people continue to die daily.
Single Doses of Psychedelics Show Lasting Relief for OCD and Anxiety in Clinical Trials
New clinical trials show single doses of psilocybin and LSD produce significant, lasting reductions in OCD and generalized anxiety disorder symptoms for up to 12 weeks, marking a potential shift from daily medication regimens.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03482232 |
Consequences of Doing What Should Not be Done in Primary Care |
COMPLETED | |
| NCT03029676 |
The Assessment of POCD After TURBT Under Spinal Anesthesia |
UNKNOWN | PHASE4 |
| NCT03012815 |
Gabapentin for Alcohol Withdrawal Syndrome |
COMPLETED | PHASE4 |
| NCT00975715 |
Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures |
COMPLETED | PHASE2/PHASE3 |